Journal of Medicinal Chemistry · 2022 · 12 citations · 27 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryPharmacodynamicsCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAdenosine-mediated SuppressionAnticancer ActivityAntitumor Immune ActivationCd8 Positive T CellsCd8 T Cell ActivationCheckpoint Inhibitor CombinationsDose-dependent Pharmacokinetic ModelsIn Vivo Studies
CD73 (ecto-5′-nucleotidase) has emerged as an attractive target for cancer immunotherapy of many cancers. CD73 catalyzes the hydrolysis of adenosine monophosphate (AMP) into highly immunosuppressive adenosine that plays a critical role in tumor progression. Herein, we report our efforts in developing orally bioavailable and highly potent small-molecule CD73 inhibitors from the reported hit molecule 2 to lead molecule 20 and then finally to compound 49. Compound 49 was able to reverse AMP-mediated suppression of CD8+ T cells and completely inhibited CD73 activity in serum samples from various cancer patients. In preclinical in vivo studies, orally administered 49 showed a robust dose-dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship that correlated with efficacy. Compound 49 also demonstrated the expected immune-mediated antitumor mechanism of action and was efficacious upon oral administration not only as a single agent but also in combination with either chemotherapeutics or checkpoint inhibitor in the mouse tumor model.
27
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard, Sandra Pommey, Mark J. Smyth et al. · Clinical Cancer Research · 2013 · 451 citations
Medicine, Oncology, Pharmacology +11
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl Hay, Erin Sult, Qihui Huang et al. · OncoImmunology · 2016 · 288 citations · Full text
Medicine, Immunology, Oncology +17